China's original new drug Phase 9 has been approved for sale, which can improve the cognitive function of Alzheimer's patients.

Alzheimer's disease occurs mostly in old age and early age, clinically characterized by memory impairment, aphasia, misuse, loss of recognition, impairment of visual spatial ability, impairment of abstract thinking and computational power, personality and behavior change, etc., is a degenerative lesions of the central nervous system characterized by sexual cognitive impairment and behavioral impairment.
With the deepening of modern medical research, it is generally accepted in the medical community that the pathological changes in Alzheimer's disease are mainly due to the formation of plaque in the brain of beta-amyloid (beta-amyloid, Beta protein), which causes neurofibrosis (NFTs) and the loss of neurons, accompanied by glial cell growth.
in recent years, the medical community's understanding of gastrointestinal flora has been gradually deepened, and a large number of studies have shown that gastrointestinal microflora disorders are closely related to nerve inflammation in Alzheimer's disease.
Phase 9 I research team has long been working on the development of anti-Alzheimer's drugs, focusing on targeting A-beta protein deposition and nerve cell Tau protein aggregation, while promoting in-depth research into the cosy mechanisms of the cerebral axis and brain disease.
original new drug Phase 9 Phase 1 is based on marine brown algae extract as raw material, the preparation of the resulting low-molecular acidic oligosaccharides compounds, through the target brain-intestinal axis to play its role in the treatment of Alzheimer's disease.
study found that Phase 9 1 improved cognitive function by reshaping the balance of the intestinal flora, reducing the production of metabolites of intestinal flora, especially phenylalanine and ialine, reducing peripheral and central inflammation, and reducing intra-brain A-beta protein deposition and Tau excessive phosphorylation.
in addition to targeting the adjustment of intestinal flora imbalance, phase 9 can also directly through the blood-brain barrier, through multiple points, multi-fragment, multi-state capture of A-beta protein, inhibit the formation of A-beta aggregates, and the formation of the aggregate splinter.
the elaboration of Phase 9 I, which provides an important scientific basis for the effectiveness and safety of Phase 3 clinical trials. A total of 1199 subjects in the
participated in phases 1, 2 and 3 clinical trials of Phase 1, 1.
3 of the clinical trials were conducted by 34 tertiary A-level hospitals in China, organized by the Shanghai Jiaotong University School of Medicine's Affiliated Mental Health Center and Beijing Concord Hospital.
3-phase clinical results over a 36-week period showed that Phase 9 1 significantly improved cognitive function in patients with light and moderate Alzheimer's disease, improved cognitive function of the main efficacy indicators compared to the placebo group, and improved the cognitive function scale (ADAS-Cog) score by 2.54 points (p.lt; 0.0001).
reporter sat in the pharmacy learned that the current nine-phase one price for a box of 895 yuan, the specification is 150mg x 14 grainx 3 boards.
if calculated according to the drug specification, the cost of 28 days in January is about $3,580, and the cost of a year is about $40,000.
because Phase 9 is a prescription drug, the specific medication plan is determined by the doctor, so the cost of medication may vary from patient to patient.
reporters in the interview was informed that in order to reduce the burden on patients and families, the nine-phase one into health care work is also being advanced.
.